NCT03557567|Completed
Loading search results
Sponsor study identifier
observational
400
0 countries
N/A
Study Start
September 29, 2014
Actual (reported)Primary Completion
April 2017
Actual (reported)Study Completion
September 2017
Actual (reported)The coming out of Next Generation Sequencing (NGS) technologies, with documented advantages and reduced costs respect to Sanger sequencing, has provided new appealing approaches to diagnostic testing. Despite this, its use for routine diagnostic purposes requires certification in terms of reliability, as well as a cost-effectiveness evaluation. To test the feasibility of using the Ion Torrent Personal Genome Machine (PGM) in clinical diagnosis, we assessed its performance to detect point mutations and big rearrangements previously identified with standard techniques. The diagnostic accuracy and the cost-effectiveness will be evaluated by Health Technology Assessment (HTA) analyses.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 29, 2014
Actual (reported)April 2017
Actual (reported)September 2017
Actual (reported)May 18, 2018
Actual (reported)June 15, 2018
Actual (reported)Assessment of the accuracy of the Ion Torrent PGM platform for genetic variant detection (Diagnostic sensitivity evaluation)
The accuracy of the Ion Torrent Personal Genome (PGM) to identify disease-causing mutations in patients affected by Multiple Osteochondromas (MO) and Osteogenesis Imperfecta (OI) needs to be validated for its routine diagnostic clinical use. To asses this, we will compare results obtained with the new NGS approach with those previously obtained with standard techniques (DHPLC/Sanger + MLPA) in a number of MO and OI patients.
at 30 months
HTA analysis to assess the cost-effectiveness, organizational and social implications of a screening strategy based on the IonPGM platform
To demonstrate the pertinence in the use of this innovative technology in health care, we will examine the medical, social and economic implications according with Health Technology Assessment (HTA), a multi-disciplinary field of policy analysis applied to many different health care technologies before their diffusion and use. HTA aims at evaluating the real effectiveness of medical interventions, their proper use, access criteria and qualitative improvements, the clinical and organizational benefits, therefore suggesting how to manage, promote and discourage them.
at 36 months
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
A total of 400 DNA samples coming from MO and OI patients (including either dominant and recessive forms) will be included in the study (250 affected by MO and 150 by OI).
whole blood
400 participants (actual enrollment reported by the registry).
First Submitted
May 18, 2018
First Posted
June 15, 2018
Study Start
September 29, 2014
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
April 2017
Actual (reported)Study Completion
September 2017
Actual (reported)Last Updated
June 18, 2018
Record last verified: 2018-06
No plan
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: